Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

72 results about "Tetramethylurea" patented technology

Tetramethylurea is the organic compound with the formula (Me₂N)₂CO. It is a substituted urea. This colorless liquid is used as an aprotic-polar solvent , especially for aromatic compounds and is used e. g. for Grignard reagents.

Preparation and application of amino-functionalized graphene oxide/azo polymer composite waveguide material

InactiveCN105218779AImprove thermo-optic performanceImprove mechanical propertiesNon-linear opticsEthylenediaminePolymer science
The invention belongs to the field of polymeric nanocomposite material synthesis, and relates to preparation and application of an amino-functionalized graphene oxide / azo polymer composite waveguide material. The preparation comprises the following steps: firstly preparing azo chromophore 4-(4-nitro-alkenyl)phenyl-1,3-diamine from paranitroaniline and m-phenylenediamine, and then preparing a isocyano-terinated azobenzene prepolymer from NAPD and IPDI in the presence of T-12; afterwards ultrasonically exfoliating graphite oxide to obtain graphene oxide dispersion liquid, and reacting with quadrol under the action of 2-(7-azo benzo triazole)-N, N, N minute, N minute-tetramethyluronium hexafluorophosphate, so as to obtain amino-functionalized graphene oxide; adding the carbimide radical blocked azobenzene prepolymer into EAGO, and performing vacuum drying. A thermo-optical coefficient (dn / dT) of the prepared amino-functionalized graphene oxide / azo polymer composite waveguide material is greater than that of a common organic material and is more than 10 times that of a traditional inorganic material, and the composite waveguide material can be applied to the development of novel digital thermal optical switches with low drive efficiency and higher response speed.
Owner:JIANGSU UNIV

Method for treating carboxylic acid-containing DMF in sucralose production

The invention relates to a method for treating carboxylic acid-containing DMF in sucralose production. The method comprises the following steps of: a, adding a small amount of sodium hydroxide into carboxylic acid-containing DMF recovered in sucralose production so as to enable the sodium hydroxide to react with the carboxylic acid-containing DMF, performing evaporating and condensing to obtain amixture containing carboxylic acid, DMF, DMA and DMAC; b, adding sodium hydroxide with an equal molar ratio into the mixture for neutralization reaction, evaporating and concentrating a reaction solution to obtain a white sodium acetate fiinshed product, and condensing evaporated gas to obtain a DMF solution without carboxylic acid; c, conveying the DMF solution without carboxylic acid into a first rectifying tower for distillation, carrying out gas-phase condensation at the top of the tower to obtain a water-containing DMF mixture, and obtaining a mixture of DMAC, tetramethylurea and impurities at the bottom of the tower; d, dehydrating the water-containing DMF mixture, and carrying out secondary rectification to obtain high-purity DMF; and e, rectifying the mixture of the bottom of the first rectifying tower again to obtain DMAC and residual liquid containing DMAC and tetramethylurea. The method has the advantages of simple process and high DMF recovery efficiency, and can avoid thegeneration of solid salt slag in traditional processes, reduce the production cost, and reduce the pollution.
Owner:ANHUI JINGHE IND

Synthesis method of spiro-oxindole gamma-butyrolactone compound

The invention relates to the field of organic chemistry and in particular relates to a spiro-oxindole gamma-butyrolactone compound IV. The spiro-oxindole gamma-butyrolactone compound IV is prepared by taking an acid shown as a formula I and acetone shown as a formula II as raw materials, and taking dichloromethane as a solvent in the presence of N,N'-carbonyl diimidazole shown as a formula III, p-toluene sulfonic acid and cesium carbonate, reacting at 25 DEG C for 4h, concentrating a reaction solution, eluting by column chromatography, collecting eluting solution parts of all detected products and carrying out rotary evaporation to remove the solvent. The invention further provides a spiro-oxindole gamma-butyrolactone compound VI which is prepared by taking the acid shown as the formula I and N-substituted isatin shown as a formula V as raw materials, and taking tetrahydrofuran as a solvent in the presence of 2-(7-benzotriazole oxide)-N,N,N',N'-tetramethyluronium hexafluorophosphate and triethylamine, reacting at 0 DEG C for 6h, concentrating a reaction solution, eluting by column chromatography, collecting eluting solution parts of all detected products and carrying out rotary evaporation to remove the solvent. A synthesis method has the advantages of relatively good yield, wide substrate applicable range, simplicity and convenience for operation, moderate reaction, convenience for post-treatment and the like.
Owner:CHINA PHARM UNIV

Positively charged water-soluble prodrugs of n-arylanthranilic acids with very fast skin penetration rate

The novel positively charged pro-drugs of arylanthranilic acids in the general formula (1) 'Structure 1' were designed and synthesized. The compounds of the general formula (1) 'Structure 1' indicated above can be prepared from mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, flunixin, and related compounds, by reaction with suitable alcohols, thiols, or amines and coupling reagents, such as N, N'-Dicyclohexylcarbodiimide, N, N'-Diisopropylcarbodiimide, O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate, O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, Benzotriazol-1-yl-oxy-tris (dimethylamino)phosphonium hexafluorophosphate, et al. The positively charged amino groups of these pro-drugs not only largely increases the solubility of the drugs, but also bonds to the negative charge on the phosphate head group of membranes and pushes the pro-drug into the cytosol. The results suggest that the pro-drugs diffuses through human skin ~200 times faster than does mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, flunixin, and related compounds. It takes 2-4 hours for mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, flunixin, and related compounds to reach the peak plasma level when they are taken orally, but these prodrugs only took about ~50 minutes to reach the peak plasma level when they are taken transdermally. In plasma, more than 90% of these pro-drugs can change back to the parent drugs in a few minutes. The prodrugs can be used medicinally in treating any NSAIAs-treatable conditions in humans or animals. The prodrugs can be administered not only orally, but also transdermally for any kind of medical treatments and thus avoid most of the side effects of NSAIAs, most notably GI disturbances such as dyspepsia, gastroduodenal bleeding, gastric ulcerations, and gastritis.
Owner:TECHFIELDS BIOCHEM CO LTD

Anti-cancer tetravalent platinum complex capable of inhibiting inflammation and immune escape and preparation method thereof

The invention provides an anti-cancer tetravalent platinum complex capable of inhibiting inflammation and immune escape and a preparation method, and particularly relates to the field of biological medicine. The molecular structure of the anti-cancer tetravalent platinum complex is as follows: S1, reacting a divalent platinum complex with hydrogen peroxide H2O2 to obtain a tetravalent platinum complex; S2, mixing the tetravalent platinum complex obtained in the step S1 with O-benzotriazole-N, N, N ', N'-tetramethylurea tetrafluoroboric acid (TBTU) and triethylamine (TEA) in an N, N-dimethylformamide (DMF) solution, and uniformly stirring and mixing; S3, after the reaction is finished, collecting a filtrate, concentrating the filtrate to 0.5-5mL, dropwise adding a mixture of ethanol and water, and centrifugally collecting precipitates; and dissolving the precipitate in methanol, washing the precipitate with diethyl ether for three times, and carrying out vacuum drying to obtain the target product. The tetravalent platinum complex disclosed by the invention not only has very strong toxic activity to tumor cells, but also inhibits inflammation and immune escape through a plurality ofaction targets, and shows an excellent anti-tumor effect in vivo.
Owner:NANJING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products